COSCIENS Biopharma Inc.
CSCIF
$2.08
-$0.08-3.92%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -20.74% | 17.63% | -27.08% | 20.10% | 62,266.67% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -20.74% | 17.63% | -27.08% | 20.10% | 62,266.67% |
| Cost of Revenue | 2.63% | 16.93% | -8.33% | -68.47% | 8,209.09% |
| Gross Profit | -43.05% | 18.93% | -51.00% | 261.08% | 12,062.50% |
| SG&A Expenses | -29.78% | -13.37% | 76.69% | 555.39% | 67.06% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -46.82% | -16.25% | 32.19% | 264.38% | 47.27% |
| Operating Income | 56.91% | 37.34% | -99.39% | -151.70% | -6.24% |
| Income Before Tax | 69.00% | -42.41% | -101.60% | -186.28% | -41.54% |
| Income Tax Expenses | -- | 100.21% | -- | 222.26% | -- |
| Earnings from Continuing Operations | 68.39% | -89.94% | -160.89% | -190.57% | -38.84% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 68.39% | -89.94% | -160.89% | -190.57% | -38.84% |
| EBIT | 56.91% | 37.34% | -99.39% | -151.70% | -6.24% |
| EBITDA | 58.76% | 38.84% | -126.25% | -144.44% | 3.39% |
| EPS Basic | 69.10% | -32.82% | -53.30% | -208.06% | 45.74% |
| Normalized Basic EPS | 64.98% | 0.41% | -18.44% | -151.96% | 58.44% |
| EPS Diluted | 69.10% | -32.82% | -53.30% | -208.15% | 45.74% |
| Normalized Diluted EPS | 64.98% | 0.41% | -18.44% | -151.96% | 58.44% |
| Average Basic Shares Outstanding | 2.28% | 42.99% | 70.20% | -16.19% | 155.89% |
| Average Diluted Shares Outstanding | 2.28% | 42.99% | 70.20% | -16.19% | 155.89% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |